Nothing Special   »   [go: up one dir, main page]

NO983189L - Nye substituerte imidazolforbindelser - Google Patents

Nye substituerte imidazolforbindelser

Info

Publication number
NO983189L
NO983189L NO983189A NO983189A NO983189L NO 983189 L NO983189 L NO 983189L NO 983189 A NO983189 A NO 983189A NO 983189 A NO983189 A NO 983189A NO 983189 L NO983189 L NO 983189L
Authority
NO
Norway
Prior art keywords
imidazole compounds
substituted imidazole
new substituted
new
compounds
Prior art date
Application number
NO983189A
Other languages
English (en)
Norwegian (no)
Inventor
Jerry L Adams
Jeffrey C Boehm
Dennis Lee
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO983189L publication Critical patent/NO983189L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
NO983189A 1996-01-11 1998-07-10 Nye substituerte imidazolforbindelser NO983189L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US990796P 1996-01-11 1996-01-11
US1495296P 1996-04-05 1996-04-05
PCT/US1997/000500 WO1997025045A1 (fr) 1996-01-11 1997-01-10 Nouveaux composes d'imidazole substitues

Publications (1)

Publication Number Publication Date
NO983189L true NO983189L (no) 1998-09-10

Family

ID=26680002

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983189A NO983189L (no) 1996-01-11 1998-07-10 Nye substituerte imidazolforbindelser

Country Status (21)

Country Link
US (3) US5756499A (fr)
EP (1) EP0900083B1 (fr)
JP (1) JP2000503302A (fr)
KR (1) KR19990077164A (fr)
CN (1) CN1213306A (fr)
AT (1) ATE247470T1 (fr)
AU (1) AU715900B2 (fr)
BR (1) BR9706973A (fr)
CA (1) CA2242327A1 (fr)
CZ (1) CZ216498A3 (fr)
DE (1) DE69724246T2 (fr)
ES (1) ES2205167T3 (fr)
HU (1) HUP9902460A3 (fr)
IL (1) IL125223A0 (fr)
MX (1) MX9805631A (fr)
NO (1) NO983189L (fr)
NZ (1) NZ327044A (fr)
PL (1) PL187516B1 (fr)
TR (1) TR199801361T2 (fr)
TW (1) TW505637B (fr)
WO (1) WO1997025045A1 (fr)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
KR19990077164A (ko) * 1996-01-11 1999-10-25 스티븐 베네티아너 신규 치환된 이미다졸 화합물
US6096739A (en) * 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
WO1998007425A1 (fr) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Composes d'imidazole, compositions les contenant et leur utilisation
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
EP1023066A4 (fr) 1997-06-13 2001-05-23 Smithkline Beecham Corp Nouveaux composes de pyrazole et de pyrazoline substitues
WO1998057966A1 (fr) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Nouveaux composes imidazole a substitution d'aryloxypymiridine
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
JP2002509537A (ja) 1997-07-02 2002-03-26 スミスクライン・ビーチャム・コーポレイション 新規なシクロアルキル置換イミダゾール化合物
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999017776A1 (fr) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Nouveaux composes substitues de cycloalcenyle
JP2001519381A (ja) * 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのｃｓａｉｄｔｍ化合物の使用
JPH11193281A (ja) * 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンａ３受容体拮抗剤およびチアゾール化合物
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
US6172106B1 (en) 1998-02-09 2001-01-09 R. Armour Forse Sesamol inhibition of Δ-5-desaturase activity and uses therefor
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
WO1999064069A1 (fr) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Anticorps anticytokiniques utilises en prevention et traitement de maladies intestinales inflammatoires
ES2221426T3 (es) * 1998-08-20 2004-12-16 Smithkline Beecham Corporation Nuevos compuestos de triazol sustituidos.
AU6476599A (en) * 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
CN1158283C (zh) 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US7122666B2 (en) * 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
WO2001038312A1 (fr) 1999-11-23 2001-05-31 Smithkline Beecham Corporation COMPOSES DE 3,4-DIHYDRO-(1H)QUINAZOLINE-2-ONE UTILISES COMME INHIBITEURS DE LA KINASE CSBP/p38
EP1233950B1 (fr) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-ones comme inhibiteurs de csbp/p38 kinase
WO2001038314A1 (fr) 1999-11-23 2001-05-31 Smithkline Beecham Corporation Composes de 3,4-dihydro-(1h)quinazolin-2-one utilises comme inhibiteurs de kinase csbp/p38
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
CA2426654C (fr) * 2000-10-23 2010-12-21 Smithkline Beecham Corporation Nouveaux composes
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
DE60207390T2 (de) 2001-03-09 2006-07-20 Pfizer Products Inc., Groton Entzündungshemmende benzimidazolverbindungen
DE60210755T2 (de) 2001-03-09 2006-11-16 Pfizer Products Inc., Groton Triazolopyridine als entzündungshemmende mittel
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
DE60205974T2 (de) 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DK1474395T3 (da) * 2002-02-12 2008-02-11 Smithkline Beecham Corp Nicotinamidderivater, der er nyttige som p38-inhibitorer
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
KR101025675B1 (ko) 2002-04-23 2011-03-30 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
EP1534282B1 (fr) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions pharmaceutiques comprenant des agents anticholinergiques etinhibiteurs de p38 kinase pour le traitement des maladies respiratoires
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
ATE343572T1 (de) * 2002-08-09 2006-11-15 Lilly Co Eli Benzimidazole und benzothiazole als inhibitoren der map-kinase
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7037923B2 (en) * 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
WO2004020438A2 (fr) * 2002-08-30 2004-03-11 Pfizer Products Inc. Nouveaux procedes et produits intermediaires pour preparer des triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US6949652B2 (en) * 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
CA2519189C (fr) 2003-05-07 2012-07-17 Osteologix A/S Sels de strontium solubles dans l'eau pour le traitement de maladies des cartilages et/ou des os
PT1635824E (pt) * 2003-06-03 2009-11-24 Novartis Ag Inibidores de p-38 à base de heterociclos de 5 membros
EP1641764B1 (fr) 2003-06-26 2011-07-27 Novartis AG Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons
EP1990338B1 (fr) * 2003-07-25 2010-09-22 Novartis AG Inhibiteurs de la kinase p-38
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US20060079461A1 (en) * 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2005080380A1 (fr) * 2004-02-03 2005-09-01 Eli Lilly And Company Inhibiteurs de la kinase
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
JP2008537937A (ja) * 2005-03-25 2008-10-02 グラクソ グループ リミテッド ピリド［２，３−ｄ］ピリミジン−７−オンおよび３，４−ジヒドロピリミド［４，５−ｄ］ピリミジン−２（１Ｈ）−オン誘導体の製造方法
UY29440A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU2006306991A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
MX2008011136A (es) * 2006-03-07 2008-09-08 Squibb Bristol Myers Co Compuestos de profamarco de pirrolotriazina anilina utiles como inhibidores de cinasa.
WO2008057775A2 (fr) * 2006-10-27 2008-05-15 Bristol-Myers Squibb Company Composés d'amide hétérocyclique utiles comme inhibiteurs de kinase
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
KR101012313B1 (ko) * 2008-06-10 2011-02-09 서울대학교산학협력단 염증질환 치료제
CN102131805A (zh) 2008-06-20 2011-07-20 百时美施贵宝公司 用作激酶抑制剂的咪唑并吡啶和咪唑并吡嗪化合物
EP2307411B1 (fr) * 2008-06-20 2014-01-01 Bristol-Myers Squibb Company Composés de triazolopyridine utilisés comme inhibiteurs de kinase
WO2011041640A1 (fr) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Compositions d'olopatadine et leurs utilisations
WO2012031057A1 (fr) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms-582949 pour le traitement d'une maladie rhumatismale résistante
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748119A (en) * 1954-06-23 1956-05-29 Searle & Co 6-furyl and 6-thienyl derivatives of 4-trifluoromethyl-2-pyrimidinamines
US3557114A (en) * 1968-12-23 1971-01-19 Merck & Co Inc 1-substituted-3-(2-pyrimidinyl) imidazolium salts
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (fr) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
AU9137591A (en) * 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
JPH06503349A (ja) * 1990-12-13 1994-04-14 スミスクライン・ビーチャム・コーポレイション 新規ｃｓａｉｄｓ
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
AU693114B2 (en) * 1993-10-01 1998-06-25 Novartis Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
WO1995009847A1 (fr) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Derives pyrimidineamine et leurs procedes de preparation
WO1995009853A1 (fr) * 1993-10-01 1995-04-13 Ciba-Geigy Ag Derives pyridine pharmacologiquement actifs ainsi que leurs procedes de preparation
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
KR19980701374A (ko) * 1995-01-12 1998-05-15 스티븐 베네티아너 신규 화합물(Novel Compounds)
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
KR19990077164A (ko) * 1996-01-11 1999-10-25 스티븐 베네티아너 신규 치환된 이미다졸 화합물
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2001508395A (ja) * 1996-01-11 2001-06-26 スミスクライン・ビーチャム・コーポレイション 新規シクロアルキル置換イミダゾール
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
JP2000507545A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
US6096739A (en) * 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
WO1998007425A1 (fr) * 1996-08-21 1998-02-26 Smithkline Beecham Corporation Composes d'imidazole, compositions les contenant et leur utilisation
WO1998022109A1 (fr) * 1996-11-20 1998-05-28 Merck & Co., Inc. Imidazoles a substitution triaryle en tant qu'antagonistes du glucagon

Also Published As

Publication number Publication date
US5756499A (en) 1998-05-26
DE69724246D1 (de) 2003-09-25
ATE247470T1 (de) 2003-09-15
BR9706973A (pt) 1999-04-06
HUP9902460A2 (hu) 1999-11-29
WO1997025045A1 (fr) 1997-07-17
CZ216498A3 (cs) 1999-08-11
ES2205167T3 (es) 2004-05-01
CN1213306A (zh) 1999-04-07
MX9805631A (es) 1998-11-30
CA2242327A1 (fr) 1997-07-17
EP0900083B1 (fr) 2003-08-20
PL327735A1 (en) 1998-12-21
KR19990077164A (ko) 1999-10-25
EP0900083A4 (fr) 1999-08-25
TW505637B (en) 2002-10-11
TR199801361T2 (xx) 1998-10-21
PL187516B1 (pl) 2004-07-30
EP0900083A1 (fr) 1999-03-10
NZ327044A (en) 2000-01-28
DE69724246T2 (de) 2004-06-03
HUP9902460A3 (en) 2000-03-28
JP2000503302A (ja) 2000-03-21
IL125223A0 (en) 1999-03-12
AU715900B2 (en) 2000-02-10
AU1577497A (en) 1997-08-01
US5977103A (en) 1999-11-02
US5864036A (en) 1999-01-26

Similar Documents

Publication Publication Date Title
NO983189L (no) Nye substituerte imidazolforbindelser
PT935465E (pt) Compostos novos de imidazole substituido
ATE233561T1 (de) Imidazolverbindungen
BR9810342A (pt) Novos compostos imidazola substituìdos
MX9805628A (es) Imidazoles novedosos substituidos con cicloalquilo.
ATE266399T1 (de) Neue substituierte triazolverbindungen
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
DE60020595D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
GB2324091A (en) Metalloproteinase inhibitors
TR200100133T2 (tr) FKBP İnhibitörleri
ATE217619T1 (de) Endothelin-rezeptor-antagonisten
UY24784A1 (es) Nuevos compuestos de imidazol sustituidos
ECSP961770A (es) Nuevos compuestos de imidazol 1,4,5 sustituidos
BG102613A (en) New substituted imidazoles
ECSP971995A (es) Nuevos imidazoles sustituidos con cicloalquilo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application